ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 65.9% in May

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 339,100 shares, a growth of 65.9% from the May 15th total of 204,400 shares. Based on an average daily trading volume, of 153,400 shares, the days-to-cover ratio is presently 2.2 days.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research analyst reports. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Guggenheim reiterated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Truist Financial boosted their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright lifted their price objective on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $81.00.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,985 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total transaction of $199,995.00. Following the transaction, the senior vice president now directly owns 77,227 shares of the company’s stock, valued at approximately $5,174,209. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Ori Gutwerg sold 2,985 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $67.00, for a total transaction of $199,995.00. Following the completion of the sale, the senior vice president now owns 77,227 shares in the company, valued at $5,174,209. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen P. Carey sold 5,000 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total value of $317,900.00. Following the sale, the chief financial officer now directly owns 161,968 shares of the company’s stock, valued at $10,297,925.44. The disclosure for this sale can be found here. Insiders have sold 156,688 shares of company stock worth $10,230,863 in the last quarter. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Pacer Advisors Inc. bought a new stake in ANI Pharmaceuticals during the fourth quarter valued at $41,000. AJOVista LLC bought a new position in ANI Pharmaceuticals in the fourth quarter worth about $58,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at approximately $106,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of ANI Pharmaceuticals by 361.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,854 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $132,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:ANIP opened at $62.62 on Friday. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The firm has a market cap of $1.31 billion, a PE ratio of 39.14 and a beta of 0.81. The company has a fifty day simple moving average of $65.09 and a 200 day simple moving average of $60.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.79 by $0.16. The business had revenue of $137.43 million for the quarter, compared to analysts’ expectations of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. On average, equities research analysts anticipate that ANI Pharmaceuticals will post 3.34 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.